Systematic Review of G-CSF and Plerixafor

Two reviewers independently extracted data from eligible studies, including the following: author, year, trial ID, patients (age and disease), administration (G-CSF and plerixafor), predetermined apheresis yield of CD34+ cells, confounding variables, and previous treatment of the patients. Data analysis was performed using the RevMan software. A meta-analysis was carried out on the data about the administration of ‘G-CSF + plerixafor’ versus ‘G-CSF alone’ or before and after the addition of plerixafor: (1) number of patients who achieved the predetermined apheresis yield of CD34+ cell count (cells × 10⁶/kg), (2) CD34+ cell count (cells/μL), and (3) number of adverse events. Subgroup analysis was performed according to the disease type. An I² > 50% was considered inappropriate heterogeneity, in which case the random-effects model was used. Statistical significance was set at p < 0.05.